Xeris Pharmaceuticals (XERS) AI Stock Analysis

• Market Cap: $1.60B
• Dividend Yield: N/A
• Average Volume (3M): 2.10M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.24
• Revenue Growth: 35.62%
• EPS Growth: 49.58%
• Country: US
• Employees: 394
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.01
• Shares Outstanding: 161,480,360
• 10 Day Avg. Volume: 1,869,518
• 30 Day Avg. Volume: 2,095,610
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.59
• Enterprise Value/Revenue: 3.83
• Enterprise Value/Gross Profit: 4.72
• Enterprise Value/Ebitda: 127.50
• 1Y Price Target: $12.33
• Price Target Upside: 35.79% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 55 Neutral
• Price Target: $7.50 ▼(-17.40% Downside)

Xeris Pharmaceuticals shows strong revenue growth and positive momentum, but significant financial challenges and valuation concerns weigh heavily on the overall score. The earnings call provided a positive outlook, but the company's financial health remains a critical risk factor.

Positive Factors

Revenue Growth

The significant revenue growth highlights strong demand for Xeris's products, indicating effective market penetration and potential for sustained expansion.

Product Demand

The exceptional growth of Recorlev underscores its importance in the company's portfolio and suggests a robust market position in treating Cushing's syndrome.

Operational Efficiency

Achieving positive adjusted EBITDA reflects improved operational efficiency, which is crucial for long-term financial stability and growth.

Negative Factors

Profitability Challenges

Struggling with profitability despite revenue growth indicates cost management issues that could hinder sustainable financial performance.

High Leverage

The high leverage and negative equity position pose significant financial risks, potentially limiting the company's ability to invest in growth opportunities.

Cash Flow Management

The decline in free cash flow growth indicates challenges in cash management, which could affect the company's ability to fund operations and growth initiatives.

Xeris Pharmaceuticals Business Overview & Revenue Model

Company Description

Xeris Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with chronic diseases. The company specializes in the delivery of biologics and has developed a proprietary formulation technology that enables the stable, room-temperature storage of biologics, which helps improve patient compliance and convenience. Xeris's core products include Gvoke, an injectable glucagon for the treatment of severe hypoglycemia, and other potential therapies aimed at addressing unmet medical needs in diabetes and other chronic conditions.

How the Company Makes Money

Xeris Pharmaceuticals generates revenue primarily through the sales of its products, particularly Gvoke, which is marketed for the emergency treatment of severe hypoglycemia in patients with diabetes. The company also earns revenue through partnerships and collaborations with other pharmaceutical companies, which may include licensing agreements, milestone payments, and royalties from product sales. Additionally, Xeris may explore opportunities in research and development agreements that can provide further financial support through funding or shared revenues from new therapies developed using its proprietary technology.

Xeris Pharmaceuticals Financial Statement Overview

Summary

Xeris Pharmaceuticals is experiencing revenue growth but faces significant profitability and cash flow challenges. The high leverage and negative equity position present financial risks. While revenue is increasing, the company needs to address its cost structure and improve cash flow management to enhance financial health.

Income Statement

Xeris Pharmaceuticals has shown a positive revenue growth rate of 10.55% in the TTM, indicating a growing top line. However, the company is struggling with profitability, as evidenced by negative net profit and EBIT margins. The gross profit margin has decreased significantly from 81.86% in 2024 to 37.11% in the TTM, reflecting increased cost pressures or pricing challenges.

Balance Sheet

The balance sheet reveals high leverage with a negative equity position, resulting in a concerning debt-to-equity ratio of -13.32 in the TTM. The negative return on equity indicates that the company is not generating profits from its equity base, posing a risk to financial stability.

Cash Flow

Cash flow analysis shows a significant decline in free cash flow growth by -75.8% in the TTM, indicating cash management challenges. The operating cash flow to net income ratio is negative, suggesting inefficiencies in converting income into cash. However, the free cash flow to net income ratio is slightly above 1, indicating that free cash flow is covering net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2023	Dec 2023	Dec 2023
Income Statement
Total Revenue	246.03M	203.07M	163.91M	163.91M	163.91M	163.91M
Gross Profit	199.62M	166.24M	135.27M	135.27M	135.27M	135.27M
EBITDA	7.39M	-11.30M	-23.73M	-23.73M	-23.73M	-23.73M
Net Income	-32.00M	-54.84M	-62.26M	-62.26M	-62.26M	-62.26M
Balance Sheet
Total Assets	334.69M	323.06M	322.60M	322.60M	322.60M	322.60M
Cash, Cash Equivalents and Short-Term Investments	59.28M	71.62M	72.45M	72.45M	72.45M	72.45M
Total Debt	257.22M	271.45M	229.19M	229.19M	229.19M	229.19M
Total Liabilities	353.99M	352.68M	329.38M	329.38M	329.38M	329.38M
Stockholders Equity	-19.30M	-29.61M	-6.78M	-6.78M	-6.78M	-6.78M
Cash Flow
Free Cash Flow	-6.64M	-37.85M	-49.29M	-49.29M	-49.29M	-49.29M
Operating Cash Flow	-6.33M	-36.98M	-47.02M	-47.02M	-47.02M	-47.02M
Investing Cash Flow	19.64M	4.88M	-6.00M	-6.00M	-6.00M	-6.00M
Financing Cash Flow	-1.88M	36.17M	-1.61M	-1.61M	-1.61M	-1.61M

Xeris Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 9.08
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XERS, the sentiment is Positive. The current price of 9.08 is above the 20-day moving average (MA) of 9.06, above the 50-day MA of 8.37, and above the 200-day MA of 5.68, indicating a bullish trend. The MACD of 0.46 indicates Negative momentum. The RSI at 74.30 is Negative, neither overbought nor oversold. The STOCH value of 81.39 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XERS.

Xeris Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
STOK	62 Neutral	$1.39B	29.99	18.17%	―	1218.82%	―
ZYME	59 Neutral	$1.38B	-18.52	-19.89%	―	95.94%	35.69%
RCUS	56 Neutral	$2.41B	-5.78	-68.13%	―	-8.75%	-8.79%
XERS	55 Neutral	$1.60B	-46.59	―	―	35.62%	49.58%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SNDX	48 Neutral	$1.33B	-4.25	-129.32%	―	2133.71%	-15.38%
RAPP	44 Neutral	$1.23B	-10.82	-29.42%	―	―	―

Xeris Pharmaceuticals Corporate Events

Xeris Pharmaceuticals Reports Record Revenue and Growth

Xeris Pharmaceuticals’ recent earnings call painted a picture of robust financial health and promising growth prospects. The company reported a record-breaking quarter with significant revenue growth and increased demand for its key products, particularly Recorlev. Despite some challenges, such as increased expenses and a slight decline in gross margin, the overall sentiment was positive, with raised revenue guidance and a favorable adjusted EBITDA.

Xeris Biopharma Reports Strong Q2 2025 Results

Xeris Biopharma Holdings, Inc., a biopharmaceutical company based in Chicago, focuses on developing and commercializing innovative therapies, including products like Recorlev, Gvoke, and Keveyis, with a robust pipeline of development programs.